# Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

> **NCT04214392** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 19 (actual)

## Conditions studied

- Recurrent Glioblastoma
- Recurrent Malignant Glioma
- Recurrent WHO Grade II Glioma
- Recurrent WHO Grade III Glioma

## Interventions

- **BIOLOGICAL:** Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)
- **BIOLOGICAL:** Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)

## Key facts

- **NCT ID:** NCT04214392
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-26
- **Primary completion:** 2026-06-09
- **Final completion:** 2026-06-09
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04214392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04214392, "Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04214392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*